IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v74y2005i3p287-303.html
   My bibliography  Save this article

The cost of epidemiological transition: A study of a decrease in pertussis vaccination coverage

Author

Listed:
  • Girard, Dorota Zdanowska

Abstract

No abstract is available for this item.

Suggested Citation

  • Girard, Dorota Zdanowska, 2005. "The cost of epidemiological transition: A study of a decrease in pertussis vaccination coverage," Health Policy, Elsevier, vol. 74(3), pages 287-303, November.
    • Handle: RePEc:eee:hepoli:v:74:y:2005:i:3:p:287-303
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(05)00031-X
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Clive Pritchard;Nancy Devlin;Adrian Towse, 2002. "Cost-Effectiveness Thresholds: Economic and ethical issues," Monograph 000473, Office of Health Economics.
    2. Carthy, Trevor & Chilton, Susan & Covey, Judith & Hopkins, Lorraine & Jones-Lee, Michael & Loomes, Graham & Pidgeon, Nick & Spencer, Anne, 1998. "On the Contingent Valuation of Safety and the Safety of Contingent Valuation: Part 2--The CV/SG "Chained" Approach," Journal of Risk and Uncertainty, Springer, vol. 17(3), pages 187-213, December.
    3. Girard, Dorota Z., 2000. "Intervention times series analysis of pertussis vaccination in England and Wales," Health Policy, Elsevier, vol. 54(1), pages 13-25, November.
    4. Stirling Bryan & Tracy Roberts & Chris Heginbotham & Alison McCallum, 2002. "QALY‐maximisation and public preferences: results from a general population survey," Health Economics, John Wiley & Sons, Ltd., vol. 11(8), pages 679-693, December.
    5. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
    6. Brada, Josef C & King, Arthur E, 1992. "Is There a J-Curve for the Economic Transition from Socialism to Capitalism?," Economic Change and Restructuring, Springer, vol. 25(1), pages 37-53.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Dorota Girard, 2010. "The distribution over time of costs and social net benefits for pertussis immunization programs," International Journal of Health Economics and Management, Springer, vol. 10(1), pages 1-27, March.
    2. Kristin Harper & George Armelagos, 2010. "The Changing Disease-Scape in the Third Epidemiological Transition," IJERPH, MDPI, vol. 7(2), pages 1-23, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Colin Green & Karen Gerard, 2009. "Exploring the social value of health‐care interventions: a stated preference discrete choice experiment," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 951-976, August.
    2. Richard Norman & Gisselle Gallego, 2008. "Equity weights for economic evaluation: An Australian Discrete Choice Experiment, CHERE Working Paper 2008/5," Working Papers 2008/5, CHERE, University of Technology, Sydney.
    3. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
    4. Martin Buxton, 2005. "How much are health-care systems prepared to pay to produce a QALY?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 285-287, December.
    5. Gu, Yuanyuan & Lancsar, Emily & Ghijben, Peter & Butler, James RG & Donaldson, Cam, 2015. "Attributes and weights in health care priority setting: A systematic review of what counts and to what extent," Social Science & Medicine, Elsevier, vol. 146(C), pages 41-52.
    6. Hugh Gravelle & Stephen Morris & Matt Sutton, 2006. "Are General Practitioners Good for Endogenous Supply and Health," Working Papers 020cherp, Centre for Health Economics, University of York.
    7. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    8. James K. Hammitt, 2020. "Valuing mortality risk in the time of COVID-19," Journal of Risk and Uncertainty, Springer, vol. 61(2), pages 129-154, October.
    9. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    10. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    11. Cairns, John, 2006. "Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared," Health Policy, Elsevier, vol. 76(2), pages 134-143, April.
    12. Martin Raiser, 1993. "Old habits die hard," Intereconomics: Review of European Economic Policy, Springer;ZBW - Leibniz Information Centre for Economics;Centre for European Policy Studies (CEPS), vol. 28(4), pages 170-177, July.
    13. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.
    14. repec:ces:ifodic:v:4:y:2006:i:2:p:14567506 is not listed on IDEAS
    15. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    16. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    17. Henderson, John & Janke, Katharina & Propper, Carol, 2007. "Are current levels of air pollution in England too high?: the impact of pollution on population mortality," LSE Research Online Documents on Economics 6205, London School of Economics and Political Science, LSE Library.
    18. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    19. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    20. Mauskopf, Josephine & Chirila, Costel & Birt, Julie & Boye, Kristina S. & Bowman, Lee, 2013. "Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?," Health Policy, Elsevier, vol. 110(1), pages 49-59.
    21. E. Stolk & M. Poley, 2005. "Criteria for determining a basic health services package," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-7, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:74:y:2005:i:3:p:287-303. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.